医学
前列腺癌
多西紫杉醇
背景(考古学)
阿比曲酮
临床试验
肿瘤科
雄激素剥夺疗法
疾病
醋酸阿比特龙酯
前列腺癌的治疗
癌症
雄激素受体
内科学
生物信息学
生物
古生物学
作者
Theodore Stewart Gourdin
出处
期刊:Current Opinion in Oncology
[Ovid Technologies (Wolters Kluwer)]
日期:2020-03-25
卷期号:32 (3): 210-215
被引量:35
标识
DOI:10.1097/cco.0000000000000624
摘要
Summarize recent advances in the treatment of advanced prostate cancer.Recent randomized data suggest a survival advantage to early use of novel androgen receptor inhibitors in combination with androgen deprivation therapy both in the setting of hormone-sensitive metastatic prostate cancer and nonmetastatic castration-resistant disease. While ongoing analyses examine optimal sequencing of existing agents for treatment of advanced prostate cancer, additional research focuses on expanding treatment options through development of novel genomically targeted therapies, antibody-drug conjugates, and immune therapy combinations.In this review, we summarize the recent data supporting the early use of novel androgen receptor inhibitors in advanced prostate cancer and aim to also frame how these drugs may fit within the existing context of docetaxel and abiraterone. We present recent series examining sequencing of approved therapies while searching for predictive biomarkers. Finally, we examine trials evaluating novel agents that target certain biological pathways to highlight the likely future directions for progress in the clinical management of advanced prostate cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI